- Trial phase
- Approved
- Time to market
- Already approved and commercialized. The original BRAVECTO chewable was approved in 2014. The latest formulation, BRAVECTO Quantum (12-month injectable), was FDA-approved on July 10, 2025.
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout) is scheduled for any BRAVECTO product in the next ~12 months. The franchise is fully approved and commercialized. As a small part of a $65B+ diversified pharma, even a material sales shift in this product line would have minimal impact on Merck's stock price. Score is 3.
With no upcoming PDUFA or pivotal readout for BRAVECTO, the next event to watch for this product line is the ongoing NARB referral to the FTC and FDA over Bravecto Quantum marketing claims, which could result in labeling or advertising restrictions. Quarterly earnings reports (next: Q4 2026, late January 2027) will show whether Bravecto Quantum is gaining traction with veterinarians and whether the established chewable/topical franchise is holding market share against Zoetis's NexGard and Simparica Trio.
Price Chart
Executive Summary
BRAVECTO is Merck Animal Health's blockbuster flea and tick protection franchise for dogs and cats, with $1.1 billion in 2025 sales. Its active ingredient, fluralaner, belongs to the isoxazoline class and is available in oral chews (12-week, 1-month), topical solutions (Bravecto Plus includes moxidectin for heartworm), and the recently approved Bravecto Quantum, a once-yearly injectable launched in July 2025. The Quantum label was expanded in March 2026 to cover two additional tick species. BRAVECTO faces stiff competition from Zoetis's NexGard and Simparica Trio and Elanco products. An ongoing ad dispute with Elanco over Quantum's 'once-a-year' claims was referred to the FTC and FDA by the NARB in May 2026. As a small but steady contributor within Merck's $65B+ diversified revenue base, BRAVECTO has no near-term binary catalysts to drive outsized stock moves.
How It Works
Fluralaner is an isoxazoline-class antiparasitic that works by overstimulating the nervous system of fleas and ticks, causing paralysis and death. It is absorbed into the pet's bloodstream and kills parasites when they bite. Different formulations provide protection ranging from one month (chews) up to 12 months (Bravecto Quantum injectable).
Trial Status
BRAVECTO is fully approved and marketed in the US and globally across multiple formulations. The newest formulation, Bravecto Quantum, received FDA approval on July 10, 2025, as the first-ever once-yearly flea and tick injectable for dogs. A label expansion was approved on March 18, 2026, adding two tick species.
The Two-Sided Case
Upcoming Catalysts
- FTC/FDA enforcement outcome following NARB referral over Bravecto Quantum advertising claims (timing uncertain)
- Quarterly earnings reports will disclose BRAVECTO line sales performance relative to growing competition
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report